Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib Doublet Therapy in Recurrent CNS Tumors
NCT03434262Phase 1Completed
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Mar 2018
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ribociclib in medulloblastoma, ependymoma, high-grade glioma (HGG) and 1 more (3 arms), sponsored by St. Jude Children's Research Hospital. Primary endpoints: Maximum Tolerated Dose / Recommended Phase 2 Dose at 1 month and Pharmacokinetics at Cycle 2. Started Mar 2018; status: completed.
02
Drugs
ribociclib
03
Conditions
medulloblastomaependymomahigh-grade glioma (HGG)central nervous system embryonal tumor
Beyond the preview
Go deeper on NCT03434262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03434262.